Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122456) titled 'Multicenter Efficacy and Safety Evaluation Study of Ultra-Short Regimens for Drug-Resistant Pulmonary Tuberculosis' on April 14.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shenzhen Third People's Hospital
Condition:
Tuberculosis
Intervention:
Experimental Group:BLSZ regimen for 2 months (9 weeks), may be extended to 3 months (13 weeks) if necessary.
Control Group:6BPaLM (26 weeks
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-01
Target Sample Size: Experimental Group:165;Control Group:165;
Countries of Recruitment:
China
To know mo...